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Abstract
Background: Internationally, many health care interventions were diffused prior to the standard
use of assessments of safety, effectiveness and cost-effectiveness. Disinvestment from ineffective or
inappropriately applied practices is a growing priority for health care systems for reasons of
improved quality of care and sustainability of resource allocation. In this paper we examine key
challenges for disinvestment from these interventions and explore potential policy-related avenues
to advance a disinvestment agenda.
Results: We examine five key challenges in the area of policy driven disinvestment: 1) lack of
resources to support disinvestment policy mechanisms; 2) lack of reliable administrative
mechanisms to identify and prioritise technologies and/or practices with uncertain clinical and cost-
effectiveness; 3) political, clinical and social challenges to removing an established technology or
practice; 4) lack of published studies with evidence demonstrating that existing technologies/
practices provide little or no benefit (highlighting complexity of design) and; 5) inadequate
resources to support a research agenda to advance disinvestment methods. Partnerships are
required to involve government, professional colleges and relevant stakeholder groups to put
disinvestment on the agenda. Such partnerships could foster awareness raising, collaboration and
improved health outcome data generation and reporting. Dedicated funds and distinct processes
could be established within the Medical Services Advisory Committee and Pharmaceutical Benefits
Advisory Committee to, a) identify technologies and practices for which there is relative
uncertainty that could be the basis for disinvestment analysis, and b) conduct disinvestment
assessments of selected item(s) to address existing practices in an analogous manner to the current
focus on new and emerging technology. Finally, dedicated funding and cross-disciplinary
collaboration is necessary to build health services and policy research capacity, with a focus on
advancing disinvestment research methodologies and decision support tools.
Conclusion: The potential over-utilisation of less than effective clinical practices and the potential
under-utilisation of effective clinical practices not only result in less than optimal care but also
fragmented, inefficient and unsustainable resource allocation. Systematic policy approaches to
disinvestment will improve equity, efficiency, quality and safety of care, as well as sustainability of
resource allocation.
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The term disinvestment in health care is gaining promi-
nence internationally. It relates to the processes of (par-
tially or completely) withdrawing health resources from
any existing health care practices, procedures, technolo-
gies or pharmaceuticals that are deemed to deliver little or
no health gain for their cost, and thus are not efficient
health resource allocations. The goal of reducing the use
of ineffective technologies or practices has been central to
Evidence-Based Medicine (EBM) for well over a decade. In
the early 1990s claims were made that in all areas of
health care, "30–40% of patients do not receive treat-
ments of proven effectiveness" [1], and, "20–25% of
patients have treatments that are unnecessary or poten-
tially harmful" [2]. Since then, advances have been made
in Australia, and internationally, to improve primarily the
safety of health care, but also clinical and cost-effective-
ness. Improvements have been achieved through the col-
laborative work of national and regional health
departments, health care institutions, professional col-
leges, academia and numerous organisations. In Australia
these include but are not limited to the National Institute
of Clinical Studies (NICS), the Australian Commission on
Safety and Quality in Health Care – formerly the Austral-
ian Council for Safety and Quality in Health Care, the
Australasian Association for Quality in Health Care
(AAQHC), Effective Healthcare Australia (EHA), and the
National Health and Medical Research Council
(NHMRC). Furthermore, health technology assessment
consultancy groups such as Adelaide Health Technology
Assessment (AHTA) are increasingly involved in support-
ing current policy processes.
Considerable effort and resources have been invested in
Australia in developing well-defined criteria and evi-
dence-based policy processes for assessing new and emerg-
ing health technologies, surgical procedures and
pharmaceuticals to gauge their safety, effectiveness and
cost-effectiveness [3,4]. Reimbursement approval (and
therefore universal access through Australia's Medicare
system) for these new services, as well as the withdrawal
of reimbursement for existing services, rests with the Aus-
tralian Government Minister for Health and Ageing under
advice from the Medical Services Advisory Committee
(MSAC) and, for pharmaceuticals, the Pharmaceutical
Benefits Advisory Committee (PBAC). The MSAC and the
PBAC employ stringent review processes based on the
existence of quality data and evidence that are available at
the time of assessment. Underpinning the disinvestment
movement, however, is a recognition that these stringent
assessment methods are relatively novel, and that the
processes to date have focused overwhelmingly on new
and emerging practices, technologies and pharmaceuti-
cals and not on existing services (even though this is
within the mandate of the MSAC). Australia therefore, like
other countries, suffers from a legacy whereby many cur-
rently implemented health care interventions were in use
prior to well-defined standards of cost-effectiveness
becoming a criterion for reimbursement. Thus there is
concern that health services of limited effectiveness may
still be in practice nation-wide. The Chief Executive
Officer of Australia's National Institute of Clinical Studies
(NICS) has stated,
We do not know how much of the total healthcare Austral-
ians receive is based on the best available evidence; studies
of a number of specific conditions show that there are gaps
between what is known and what happens in practice [5].
While processes such as clinical practice guidelines devel-
opment and implementation continue to tackle aspects of
this problem, disinvestment focuses on a complementary
but parallel facet by examining practices that should be
reduced or in some cases eliminated completely. We clas-
sify the principal challenges for disinvestment as follows:
1) Lack of dedicated resources by key stakeholders to
build and support disinvestment policy mechanisms
2) Lack of reliable administrative mechanisms to identify
and prioritise technologies and/or practices with relative
uncertainty as to their clinical and cost-effectiveness
3) Political, clinical and social challenges to removing an
established technology (including challenges to limiting
coverage to specific patients, institutions, or providers)
4) Lack of published studies that clearly demonstrate that
existing technologies/practices provide little or no benefit
5) Inadequate resources to support a research agenda to
advance disinvestment methods
Discussion
The following discussion will examine some of the ele-
ments involved in addressing these challenges. The dis-
cussion will highlight what is occurring currently with
implications for what ought to occur in order to support
effective disinvestment. We will present two brief case
studies to illustrate several complexities with accompany-
ing recommendations.
1) Lack of dedicated resources by key stakeholders to build and
support disinvestment policy mechanisms
The bearer of financial risk for the cost of healthcare per-
haps has the greatest incentive to drive a disinvestment
agenda. In the USA this might include public and private
payers, purchasers or large employers. Whereas in govern-
ment managed or mixed-model health care systems itPage 2 of 8
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insurance industry. In Australia, the MSAC faces issues in
its current policy processes and capacity to support effec-
tive disinvestment. While for new devices or pharmaceu-
ticals the burden for proving effectiveness lies with the
sponsor, for potentially obsolete technology or practices,
the opposite occurs. The regulator or payer (the Australian
government with advice from the MSAC) firstly has to
identify or be made aware of a doubtful practice, to com-
mission reviews, and then to mount a compelling argu-
ment for ineffectiveness and/or cost-ineffectiveness. For
illustrative purposes this may be described as somewhat
analogous to standards of law. That is, adding an item to
the schedule of benefits (or its equivalent in international
terms) is beholden to a 'balance of probabilities' standard
whereas removal of an item requires a standard of evi-
dence that is 'beyond reasonable doubt'. As will be dis-
cussed further, this identification and appraisal process is
in itself complex, but even if it were not, the MSAC has a
full agenda with applications for new and emerging tech-
nologies and hence has limited capacity to address exist-
ing services. This is evident in communications with the
MSAC members that highlight their workload, and the
focus of that work. At a recent meeting of the MSAC, the
22 committee members were faced with 700 pages of doc-
umentation to consider. All of that material was for new
and emerging technologies and practices; none was for
existing, potentially ineffective health care. In Australia we
therefore appear to be 'stuck with the old and over-
whelmed by the new'. Irrespective of the successes the
Australian policy model has had in assessing new and
emerging technologies, there appears to be a lack of capac-
ity to address both new and existing practices. Or arguably
the capacity exists but is not being appropriately har-
nessed at present, which may reflect a lack of political will.
In any case disinvestment is limited. This limitation in
capacity may be, in part, a result of the political and pro-
fessional complexities associated with disinvesting exist-
ing practices (discussed further below). It also points to
the growing need for a political paradigm shift in order to
foster policy-driven disinvestment capacity.
2) Lack of reliable administrative mechanisms to identify and
prioritise technologies and practices for which there is relative
uncertainty as to clinical and cost-effectiveness
Disinvestment may be easier with pharmaceuticals and/or
when adverse events occur. The process is more complex
when individual are not harmed by existing practices but
over-treated or ineffectively treated. That is, subjected to
diagnosis or treatment that is safe but of little or no mean-
ingful clinical benefit (i.e. supported by the existence of
compelling clinical- and cost-effectiveness evidence). A
register for 'ineffectively-treated' does not exist in the same
way as an adverse event register exists for pharmaceuticals,
or an adverse event register within tertiary care settings.
Further compounding this issue is the limited number of
groups in Australia (or indeed elsewhere) with a clear
directive and sufficient resources or incentive to seek out,
identify and investigate potentially redundant/ineffective
procedures. Wilensky has recently intimated that similar
limitations (and potential for improvement) exist in the
United States of America (USA) [6]. This reflects a view
that substantial additional investment is required to sup-
port evidence-based review of not only new and emerging
but also existing health care technologies, including com-
parative studies examining new versus existing practices.
In Australia the incentive pendulum supports diffusion
and not retraction or 'disinvestment'. The current MSAC
model appears geared (and effectively so) toward control-
ling the tap as it is turned on, not toward neutralizing the
flow through active disinvestment. It is interesting for
example, that old technologies or practices are not for-
mally de-commissioned as new items are approved.
Instead, the range of options grows ever larger. And
although some (including at least one of the current
authors) purport that many practices simply fade away or
die a slow death, the question remains whether this repre-
sents a sound policy approach to resource allocation and
clinical excellence in health care.
Currently the MSAC provides advice on whether a pro-
posed new service is as or more safe, effective and cost-
effective than a comparator. There is nothing to stop the
MSAC from recommending the removal of one service as
it recommends addition of another service to the reim-
bursement schedule should the new service have demon-
strably better cost effectiveness for a given indication. That
the comparator is not automatically removed from the
schedule highlights a challenging issue for a disinvest-
ment programme. The new service (even if superior) may
take time to diffuse into practice and become accepted by
the medical profession. Premature disinvestment of the
comparator may disadvantage patients where the new
service was not yet available and thereby raise issues of
access and equity. The evidence supporting the new tech-
nology may not go as far as assessing the cost-effectiveness
of disinvestment of its comparator (in terms of capital
investment, training, and changes to clinical workflow).
Decision-making in disinvestment must take account of
these factors.
3) Political, clinical and social challenges to removing an estab-
lished technology (including challenges to limiting coverage to
specific patients, institutions, or providers)
For existing technologies or practices there are complexi-
ties that do not beset those that are new or emerging.Page 3 of 8
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example:
• Resistance to change due to established clinical training
and practice paradigms
• Multiple clinical, consumer and political interests
• Clinical and consumer influence and preferences, and
supplier-induced demand
• Incentive and disincentive mechanisms
• The sunk costs of human and physical capital which
would thereby become obsolete
Schon describes how social systems work hard to resist
change, a phenomenon he labels 'dynamic conservatism'
[7]. Research and applied decision making in this area
must therefore include analysis of the evidence for safety,
effectiveness and cost-effectiveness as well as social, ethi-
cal and political analyses to explain why ineffective health
care practices persist. Only then is there scope to address
how ineffective practices can be disinvested.
For the clinician there is often concern that disinvestment
represents a blunt instrument of rationing, one that may
restrict clinical autonomy and reduce patient choice. But
can continued investment in health care occur without
thoughtful, measured disinvestment? There is an eco-
nomic imperative to do so for the sake of sustainability.
There is also an ethical imperative for the delivery of qual-
ity health care and a best practice imperative for clinical
purchasers and providers. Disinvestment will free up
resources for those practices that have demonstrated effec-
tiveness. Furthermore, disinvestment should not be seen
as an all or nothing approach. Removing a reimbursement
item number from the Schedule of Medical Benefits (or
the equivalent action in international terms) would be an
extreme example of successful disinvestment. There may
well be a policy-guided process of measured retraction
including restricting the indications for particular services.
Important in any disinvestment policy model is recogni-
tion and consideration of perceived threats that may be
raised by disinvestment. We have included a case study
involving Assisted Reproductive Technologies (ART) for
women over the age of 42 years to explore some potential
threats and argue that these are legitimate considerations
in a disinvestment analysis (See Table 1).
There is clear evidence of limited effectiveness for ART
with increasing maternal age. There are also social, politi-
cal and ethical considerations that any disinvestment
strategy (and methodological framework) must take into
consideration. The complexities involved in any potential
disinvestment analysis of this issue support the need for
methodological advances in this area of health services
research. Such advances are required if health services
such as ART are to be moved out of the 'too hard basket'
and into active assessment, debate and appraisal.
Another barrier to disinvestment is the notion that medi-
cal technology has provided good value for money over
time, and that regulators' efforts to restrict coverage (or
disinvest) may reduce incentives for investment and inno-
vation, thereby impeding the future flow of valuable tech-
nologies [8]. We may need to tolerate a certain level of
payment for low value or relatively ineffective technolo-
gies and practices because such is the market environment
that makes possible the valuable medical breakthroughs.
4) Lack of published studies that clearly demonstrate that exist-
ing technologies/practices provide little or no benefit
For many technologies and practices there is evidence sup-
porting varying degrees of effectiveness when used in cer-
tain contexts (for example to certain patient groups with
varying degrees of predictive prognoses). However, there
are also examples of inappropriate application of other-
wise effective technologies or procedures, culminating in
Table 1: Case Study 1 Assisted Reproductive Technologies (ART) for women over 42 years of age
ART does not specifically affect morbidity or mortality (with some exceptions). The debate has, and continues, to occur prominently in the broad 
community as well as government. In 2003, age-specific success rates of In Vitro Fertilisation (IVF) cycles using fresh oocytes were [28]:
• 27.7% for women aged 25–29
• 24.9% for women aged 30–34
• 17.1% for women aged 35–39
• 6.8% for women aged 40–44
• 2% for women aged ≥ 42 (some clinics have cited success rates of 5–10%)
This success rate for women aged 42 years or more has been cited by one Australian clinic as a reason for refusing to treat women of that age [29]. 
Politicians have also engaged with this debate. In April 2005 the Australian Government Minister for Health and Ageing considered limiting ART 
funding under Medicare to three cycles per year for women 42 and under, and to three cycles in total for women over this age [30]. Rising 
expenditure on ART and the low age-specific success rates were cited as justification for this policy. This proposal for reduced support was 
subsequently abandoned by the Australian Prime Minister in May 2005. Table 3 further explores some of the methodological issues associated with 
this as a potential case study in disinvestment.Page 4 of 8
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ble examples of this are presented in the work of Wen-
nberg, disseminated in the Dartmouth Atlas highlighting
geographic variation in the use of a range of procedures
[9]. Under such conditions a degree of measured retrac-
tion of practice is desirable, with resultant disinvestment.
Clinical practice modification and refinement techniques,
perhaps via clinical practice guideline development and
implementation, have demonstrated efficacy. As noted by
Miles and co workers,
clinical practice guidelines remain, when certain conditions
are met and their limitations fully understood, useful vehi-
cles for implementing agreed changes to clinical practice
and service provision. Certainly, the process of deriving and
implementing clinical practice guidelines has developed
into a science in its own [10].
However, for some technologies or practices the evidence
for effectiveness is either less clear, or is negative, yet the
practice persists. In these instances, partial or complete
removal (from funding) may be necessary. Substantial
challenges exist, particularly around adequate and timely
definition and acceptable proof of inferiority. This is not
only conceptually difficult but also limited by data avail-
ability and interpretation. Further complicating this is the
lag that often exists in the reliable reporting of health out-
comes data based on clinical practice. Table 2 (Case Study
2) presents a case highlighting potential complexities of
'evidence' in disinvestment review decisions. These,
together with considerations from the ART example, are
further addressed in Table 3.
Within this context there is scope for expanding the capac-
ity to conduct primary and secondary research of stand
alone and comparative effectiveness for existing as well as
new technologies [11,12]. The disinvestment considera-
tions highlighted in Table 3 require methodological
advances but also time for thorough and rigorous review.
In such cases there may be potential for a 'funding with
evidence generation' mechanism (also called 'only in
research' in the United Kingdom (UK) and 'coverage with
evidence development' in the USA). This approach is cur-
rently applied for some emerging technologies but could
be adapted for existing practices. Here, payers/regulators
may allow ongoing funding only for a defined period of
time to allow for the generation and/or analyses of neces-
sary evidence. Currently there is provision for use of this
approach with new technologies by the MSAC.
5) Inadequate resources to support a research agenda to
advance disinvestment policies and methods
The discussion thus far highlights the need for methodo-
logical advances to support disinvestment decision mak-
ing. In Australia, health technology assessment groups
conduct and present the synthesised, evidence-based
reviews that support the MSAC and the PBAC reimburse-
ment decisions for new and emerging technologies and
pharmaceuticals. Health Technology Assessment (HTA)
incorporates multidisciplinary fields of policy analysis,
and has broadened, "from primarily addressing effectiveness
and safety issues to covering a broader array of issues such as
psychological, organizational, ethical and legal aspects" [13].
HTA studies the medical, social, ethical, and economic
implications of development, diffusion, and use of health
technologies, practices and services. HTA agencies
together with health services and policy researchers gener-
ally, are well positioned to take a lead role in supporting
the disinvestment of existing, ineffective health care prac-
tices. To do this effectively requires collaborative research
and recently announced funding increases from the
National Health and Medical Research Council
(NHMRC) for Health Services Research offers potential
here. But in Australia HTA groups largely operate as con-
tract research organisations and with relatively short-term
contracts these groups tend to lack capacity to build or
support a broad methodological research agenda for the
Table 2: Case Study 2 Upper airway surgical procedures for adult Obstructive Sleep Apnea (OSA)
Approximately one in five adults has at least mild OSA and one in 15 adults has OSA of moderate or worse severity [31]. The condition is an 
independent risk factor for substantial morbidity(ies) with implications also for mortality [32]. Currently, upper airway surgery is a second-line 
treatment alternative to an established non-surgical gold-standard. A recent meta-analysis of these surgical procedures reported success rates at 
[33]:
• 13% for Phase I procedures (including uvulopalatopharyngoplasty [UPPP], laser-assisted uvulopalatoplasty [LAUP], hyoid suspension [HS], 
genioglossus advancement [GA], and radiofrequency volume reduction of soft tissue [RFVR])
• 43% for advanced Phase II procedures (maxilla and/or mandible advancement (MMA) requiring up to three days Intensive Care Unit recovery).
• Two reports of patient satisfaction highlight that surgery has a high postoperative morbidity rate, a high patient-reported failure rate and a low 
level of satisfaction with 53% [34] and 61% [35] patient-reported 'regret' rates.
• The Cochrane review in this area [36] supports the restricted use of these operations and yet Australian Medicare data highlights that these 
procedures are widespread and increasing.
Despite the existence of these procedures for over a decade, debate regarding their efficacy has recently intensified, as to whether these success 
rates presented above represent 'highly effective treatment', sufficient enough to confer improved health outcomes [37-39]. Disagreement has 
occurred primarily between relevant medical specialties (i.e. surgeons and sleep medicine physicians). Importantly, there has been a lag in 
presentation of the necessary evidence to inform and advance such a debate, principally as no policy group has been assigned a stake in the 
collection or generation of such evidence, hereto it has accrued via the noble but ad hoc actions of clinical groups.Page 5 of 8
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This phenomenon is not restricted to Australia, and as
Lehoux has observed, the involvement of academic insti-
tutions in HTA has the potential to bring with it conflict-
ing legitimacies between the production of traditionally
scientific versus user-oriented knowledge [8]. With con-
certed capacity building and research initiatives aimed at
improving linkage and exchange between policy advisors/
makers and academic researchers (HTA specialists), prior-
ity driven, contextually relevant research would be facili-
tated and could support decision-making processes that
policy makers need. Moreover, it would contribute much-
needed methodological advances and align with the four
main characteristics of action research defined by Hart
and Bond [14]: (1) collaboration between researchers and
practitioners; (2) solution of practical problems; (3)
change in practice; and (4) development of theory.
Collaborative models amenable to disinvestment strate-
gies are increasingly being developed and adopted inter-
nationally, with some based on the priority setting
developments described by Mooney [15,16]). The strate-
gic 'Linkage and Exchange' and 'Participatory Action
Research' programs in Canada [17-21] deal with similar
issues. Recently, the UK's National Institute for Clinical
Excellence (NICE) announced a formal policy agenda to
"purge from the NHS treatments that do not improve health or
are poor value for money" [22]. It is interesting to note how-
ever that subsequent to the NICE disinvestment agenda
being released, a formal UK Treasury report into UK
health research and funding highlighted the challenges
faced:
The delivery of robust scientific appraisal for technologies is
coming under increasing challenge as a result of its reliance
on methodologies that, it is widely recognized, need further
development, given that Health Technology Assessment
(HTA) is a relatively new science. Appropriate research is
required to address these challenges. In particular, research
into methodology for... disinvestment methods ([23], page
103)
In the United States the 'Developing Evidence to Inform
Decisions about Effectiveness' (DeCIDE) Research Net-
work has been implemented to support the development
of new scientific knowledge through research on the out-
comes of health care items and services. This is a clear pol-
icy directive in line with Section 1013 of the Medicare
Modernization Act of 2003. Wilensky has commented
that a window of opportunity currently exists in the USA
for the development of a Center for Comparative Effec-
tiveness, particularly to address pharmaceuticals [6]. We
believe the greater challenge is to incorporate the assess-
ment of existing health care practices and technologies, as
well as pharmaceuticals. Fundamental to this is an
expanded process of medico-vigilance – monitoring of
whether the practice/technology is not only safe but effec-
tive and cost-effective in 'real' use outside the tightly con-
trolled environments in which initial evidence may have
been collected. Beyond this the social, ethical and politi-
Table 3: Investigative issues associated with the chosen health care practices
Health Care 
Technology/Practice
Setting Interest from methodological and 
policy perspectives*
Key Issues







- Marginal clinical and cost-effectiveness (on population 
basis) but limiting its use poses problems: it is highly 
beneficial from perspective of concerned individuals
- Therapy has equivocal purpose
- Highly valued by recipients and potentially by society 
broadly
- Ability to pay: user vs society
- Equity of access
- Medical vs social infertility
- Opportunity cost
Upper airway surgery 
for adult OSA








- Limiting its use should not, in theory, pose any 
problems, but pressures are strong from clinical interest 
groups
- Complex practice paradigms/incentives
- Small, homogeneous craft group
- Equipoise/clinical uncertainty
- Perspectives of patients who value the potential of a 
surgical 'fix'
- Is this preference based on sound evidence or supplier 
induced demand?
- Opportunity cost
*Key: ? = Unsure or in question; x = Limited or evidence in the negative; √ = Evidence in the positivePage 6 of 8
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nents of any disinvestment analysis.
Based on this discussion we present the following recom-
mendations of initiatives to be implemented in Australia
(and internationally where appropriate):
♣ Government partnerships to involve the professional
colleges and relevant stakeholder groups (consumer/com-
munity) to put disinvestment on the agenda including
awareness, collaboration and improved health outcome
data generation and reporting (ongoing medico-vigi-
lance).
♣ Dedicated funds and distinct processes (i.e. transparent
legal framework) within the MSAC and where appropriate
the PBAC to:
❍ Identify technologies and practices for which there is
relative uncertainty for disinvestment analysis/review
❍ Conduct disinvestment assessments/reviews of the
selected item(s)
This should involve an expanded capacity for these com-
mittees (or others adopting a similar model) to address
existing practices in an analogous manner to their current
focus on new and emerging technologies, practices and
pharmaceuticals.
❍ At this juncture in Australia's health policy landscape,
collaborative links to advance disinvestment should be
made between the relevant stakeholder bodies, including:
the MSAC/PBAC, state departments of health, the Austral-
ian Commission on Safety and Quality in Health Care,
the National Institute of Clinical Studies (and the
NHMRC more broadly).
♣ For existing health care services for which there is rela-
tive uncertainty, consideration for the implementation of
'funding with evidence generation'. That is, ongoing reim-
bursement only agreed for a limited number of years
pending evidence generation/review processes – with the
possibility of extensions being considered.
♣ Dedicated funding and cross-disciplinary collaboration
to build health services and policy research capacity with
a focus on advancing disinvestment research methodolo-
gies and decision support tools for policy stakeholders.
Disinvestment from existing health care practices that
offer little or no health gain is a policy challenge that
requires greater attention, both for quality of care and sus-
tainable resource allocation. Disinvestment may well
depend less on the availability of resources than on the
political will to support work in this area.
Summary
Australia currently has limited systems in place to support
the disinvestment of currently used ineffective, or inap-
propriately applied, health care practices. With the grow-
ing burden of chronic health conditions, addressing this
limitation should be recognised as an emerging national
priority area [24]. This discussion piece is intended to
stimulate further debate in this area (see also [25-27]).
The potential over-utilisation of less than effective clinical
practices and the potential under-utilisation of effective
clinical practices not only result in less than optimal care
but also fragmented, inefficient and unsustainable
resource allocation. Systematic policy approaches to dis-
investment will improve equity, efficiency, quality and
safety of care, as well as sustainability of resource alloca-
tion. Developing health services and policy research
methodologies that tackle these complexities to assist pol-
icy-makers will advance the disinvestment agenda. This is
a growing area of priority setting in health care that
requires national and international perspectives, debate
and collaboration.
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